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Background
Human immunodeficiency virus (HIV) infection is associated with increased cardiovascular risk, and this risk correlates with markers of monocyte activation. We have shown that HIV is associated with a prothrombotic monocyte phenotype, which can be partially mitigated by statin therapy. We therefore explored the relationship between oxidized LDL particles and monocyte activation.
Methods
We performed phenotypic analysis of monocytes using flow cytometry on fresh whole blood in 54 patients with HIV and 24 controls without HIV. Plasma levels of oxLDL, soluble CD14, IL-6, soluble CD163 were measured by ELISA. In vitro experiments were performed using flow cytometry.
Results
Plasma levels of oxLDL were significantly increased in HIV-infection compared to controls (60.1 units vs 32.1 units, p<0.001). Monocyte expression of the oxLDL receptors, CD36 and Toll-like receptor 4, were also increased in HIV. OxLDL levels correlated with markers of monocyte activation, including soluble CD14, TF expression on inflammatory monocytes, and CD36. In vitro, stimulation with oxLDL, but not to LDL, resulted in expansion of inflammatory monocytes and increased monocyte expression of TF, recapitulating the monocyte profile we find in HIV disease.
Conclusions
OxLDL may contribute to monocyte activation and further study in the context of HIV
A C C E P T E D
Introduction
Immune activation and inflammation are hallmarks of chronic HIV infection; 1, 2 and even in the setting of combination antiretroviral therapy (ART) and well-controlled viremia, markers of inflammation and immune activation often remain elevated [2] [3] [4] . Numerous studies have demonstrated that markers of inflammation 1, 5, 6 , coagulation 1, 7, 8 and indices of T cell and monocyte activation 2, 9 are independently associated with morbidity and mortality in HIV-infected patients.
Inflammation and leukocyte activation are important contributors to cardiovascular disease (CVD) and thrombotic risk in the general population [10] [11] [12] . Increased inflammation may contribute to greater risk for both venous 13, 14 and arterial 15 thromboembolic events in HIV-infection. We, and others, have found increased expression of the procoagulant tissue factor (TF) on the surfaces of monocytes 16, 17 and platelets 18 and within the circulation as microparticles 4, 19 . Among HIV-infected patients, D-dimer levels correlate with proportions of TF+ monocytes 16 and with plasma levels of sCD14 17 , suggesting a link between monocyte activation and coagulation.
We have previously reported that a similar profile of monocyte activation is observed in HIV-uninfected patients with acute coronary syndromes (ACS) 17 . , and proportions of these cells are independent predictors of cardiovascular events in HIV-uninfected subjects 21 .
Enrichment of these monocyte populations have been described in inflammatory conditions including: chronic kidney disease, atherosclerosis, sepsis, rheumatoid arthritis, and HIV disease [21] [22] [23] [24] [25] . What remains to be elucidated in each of these disease states, given distinct pathologic pathways, are the mechanisms driving monocyte activation and differentiation. A number of potential drivers of immune activation have been suggested in treated HIV infection, including low level HIV replication, systemic translocation of bacterial products from the damaged gastrointestinal tract, the presence of copathogens, and homeostatic responses to cytopenia 3 . As many HIV-infected patients also have altered lipid and metabolic profiles 26, 27 , we sought to explore the role of inflammatory lipids in the activation of monocytes in HIV disease.
Methods
Patients
These studies were performed in compliance with the Institutional Review Board at 
Flow Cytometry
Monocytes subsets were identified by size, granularity, and by expression levels of CD14 and CD16. Fluorescence minus 1 and isotype gating strategies were used to identify expression of surface markers as previously reported 17 .
Cell surface molecule expression was monitored using the following fluorochrome- 
Measurement of ox-LDL, IL-6, sCD14, and sCD163
Fresh whole blood samples were collected in EDTA containing tubes and were centrifuged for 15 minutes at 495x g. Plasma was removed and frozen at -80 o C until thawed once and analyzed in batch. Levels of soluble CD14, soluble CD163, and IL-6
were measured using Quantikine ELISA kits (R&D Systems Minneapolis MN). The interassay variability ranged 0.4-8.6%, 0.7-18.3%, and 2.02-15.36%, respectively. Levels of oxLDL were also measured by ELISA (Mercodia Uppsala, Sweden);the intra-assay variability ranged 7.4-8.3%.
Statistical Methods
We used conventional measures of central location and dispersion to describe the data.
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We compared group medians using Mann-Whitney's U test or one-way ANOVA with repeated measures where appropriate. We evaluated correlations between pairs of continuous variables using Spearman's rank correlation. All comparisons are two-sided without formal correction for multiple comparisons, and p values <0.05 were considered statistically significant. Differences in gender and race between the populations were compared using a Chi-square test.
Results
Initial studies measuring plasma markers of inflammation and oxidized LDL were performed on samples from 54 HIV-infected patients and 24 healthy donors not known to be HIV-infected. Demographic information is displayed in Table 1 ; in brief, 26% of the HIV-infected patients were female, 34% were Caucasian. Their median age was 44 years, 91% were receiving ART; median CD4+ T cell count and plasma HIV-1 RNA level were 534 cells/µl and 48 copies/mL, respectively. Among the uninfected donors, 67% were female, 75% were Caucasian, and the median age was 38 years.
Compared to the HIV-infected population, the uninfected donors were slightly younger (p=0.04), more often female (p=0.002), and more often Caucasian (p=0.025).
The median plasma levels of oxLDL were increased in HIV-infected patients (60.1 units/L, N=49) compared to levels among uninfected donors (32.1 units/L, N=19, p<0.001, Figure 1A ). Among the HIV-infected donors, oxLDL levels correlated with levels of LDL (r=0.66, p<0.001) and total cholesterol (r= 0.45, p=0.005), but not with We also measured plasma levels of IL-6 and sCD14, as these markers have been associated with all-cause mortality 1, 2 , and cardiovascular events 29 in HIV-infected patients. Not surprisingly, levels of IL-6 ( Figure 1B ) and sCD14 ( Figure 1C ) were both increased in HIV-infected patients (p=0.02, and p<0.001). We also measured sCD163, as it has been associated with non-calcified coronary artery plaques 30 , with perivascular fat 31 , and with arterial inflammation in HIV-infected subjects 32 . Levels of sCD163 also tended to be increased in patients, but this increase did not reach significance (p=0.06, Figure 1D ). Among HIV-infected patients, plasma levels of oxLDL and sCD14 were related (r=0.51, p=0.0004, Figure 1E) Figure 2A ). Among both donor groups, the proportion of monocytes expressing CD36 is lowest among the patrolling monocyte subset, however, for each monocyte subset, the proportion of CD36+ cells is greater in the HIV+ subjects (p<0.04 for all, Figure 2B ). Measurement of TLR6 was not Among patient samples, plasma LDL levels were related to %CD36+CD14+CD16-r=0.64, p=0.01, CD36+CD14+CD16+ r=0.61, p=0.02).
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To explore further the role of oxLDL in activation of monocytes, we performed ex vivo stimulation assays, where whole blood samples from uninfected donors were left unstimulated, or were exposed to LPS (20ng/ml), naïve LDL (50ug/ml) or oxLDL HIV+ patients than were inflammatory markers 36 . We propose that oxidized low-density lipoprotein may play a role in monocyte activation in HIV disease.
We report here that HIV-infected patients have increased plasma levels of oxLDL confirming a previous report 37 . A relationship between plasma levels of oxLDL and carotid intima-media thickness (CIMT) has also been reported in HIV disease 38 .
Increased levels of oxLDL have also been observed in HIV-uninfected patients with acute coronary syndromes (ACS) or with stable coronary artery disease (CAD) 39 .
Oxidized LDL uptake by macrophages within unstable coronary plaques has been found in persons with acute myocardial infarction 40 . We have reported previously that in HIVinfection and among uninfected persons with ACS there are alterations of monocyte subsets and a procoagulant phenotype 16, 17 . Thus, elevated levels of oxLDL in both patient populations may be a driving force that contributes to the shared monocyte . Previous studies found that oxLDL can induce TF expression on endothelial cells 43 and monocytes 44 , increasing procoagulant activity. Here, we confirm that TF expression is increased on monocytes following exposure to oxLDL. We show for the first time, that exposure of monocytes to oxLDL results in an increased proportion of CD14+CD16+ cells, a cell type that is proportionally enriched in HIV-infected patients 17 and is predictive of cardiovascular events in HIV-uninfected patients 21 . Baker et al recently found that the proportion of CD16+monocytes predicted coronary artery calcium progression in HIV-infected persons 45 .
We report that CD36, TLR4, and TLR2 are expressed on all three monocyte subsets 20 and that expression of CD36 and TLR4 is increased on monocytes among HIV-infected patients; and that plasma levels of oxLDL also appear to be directly related to expression of CD36 on monocytes in HIV-infected patients. Plasma levels of oxLDL were also directly related to sCD14, a marker of monocyte activation that has been linked to mortality in HIV disease 2 . This novel finding may provide insights into the drivers of sCD14 expression and provide targets for therapeutic intervention.
Statins have previously been associated with anti-inflammatory effects including the reduction of CRP 46 and diminished monocyte TLR4 expression 47 . We recently demonstrated that rosuvastatin treatment reduces sCD14 levels and monocyte TF expression in ART-treated HIV+ patients 48 .
Statins have been associated with reductions in oxLDL in HIV-uninfected populations 49 ; thus, it is tempting to speculate that the anti-inflammatory action of statins may operate, in part, through the attenuation of oxLDL-mediated monocyte activation.
Our current study has limitations; the cross-sectional nature does not enable us to measure changes in oxLDL levels over time or during modifications to ART. The donor populations are not ideally matched, with more women and Caucasians among the uninfected donors than among the patients, however, when we compared levels of oxLDL, IL-6, sCD14, and sCD163 between women donors in the HIV infected (N=14) and uninfected groups (N=14), levels of these markers remained increased among HIV+ donors (P=0.0004, 0.07, 0.008, and 0.04, respectively). We also did not measure 
